• BioXcel Therapeutics Inc BTAI.OQ BTAI.O is expected to show a rise in quarterly revenue when it reports results on March 10 (estimated) for the period ending December 31 2024

• The New Haven Connecticut-based company is expected to report a 87.9% increase in revenue to $706.67 thousand from $376 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for BioXcel Therapeutics Inc is for a loss of $6.38 per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for BioXcel Therapeutics Inc is $32.00​, above​ its last closing price of $2.74. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated March 7 at 12:45 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)